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Abstract
Background: Disseminated Intravascular Coagulation (DIC) complicates up to 7% of
malignancies, the commonest solid organ association being adenocarcinoma. Transitional Cell
Carcinoma (TCC) has rarely been associated with DIC.
Case presentation: A 74-year-old woman with TCC bladder and DIC was found to have a
cardiac lesion suspicious for metastatic disease. The DIC improved with infusion of plasma and
administration of Vitamin K, however the cardiac lesion was deemed inoperable and chemotherapy
inappropriate; given the patients functional status. We postulate that direct activation of the
coagulation cascade by the intraventricular metastasis probably triggered the coagulopathy in this
patient.
Conclusion: Cardiac metastases should be considered in cancer patients with otherwise
unexplained DIC. This may influence treatment choices.
Background
DIC is characterised by the widespread activation of coag-
ulation. This in turn results in intravascular formation of
fibrin and ultimately thrombotic occlusion of small to
medium sized vessels [1]. The commonest causes are sep-
sis and trauma. Malignancy is a well recognised cause of a
prothrombotic state, with DIC occurring in up to 7% of
solid organ tumours[2]. It is most frequently associated
with adenocarcinomas such as pancreatic, breast and
prostate cancer. Transitional cell carcinoma is rarely asso-
ciated with DIC, with very few reports in the literature.
Case presentation
A 74 year old woman presented with a two day history of
haematuria and increasing lethargy one month following
palliative radiotherapy to the bladder for a T4 Grade III
urothelial carcinoma. Clinical examination revealed large
ecchymoses over both upper and lower limbs as well as
oral mucosal bleeding without any evidence of petechiae.
The patient was apyrexial and vital signs were all within
normal limits. There were no other significant findings on
cardiovascular, respiratory and abdominal examination.
Laboratory analysis revealed INR 2.7 (normal range: 0.9–
1.3), APTT 73 sec (25–38) D-dimer 25 µg/mL (0–0.2),
fibrinogen <0.05 g/L (1.5–4.0), platelets 25 × 109/L (150–
400), consistent with disseminated intravascular coagula-
tion (DIC). Computerised tomographic (CT) scan of the
thorax and abdomen revealed a lesion within the right
ventricle (Figure 1) without other evidence of metastatic
disease within the pulmonary or hepatic parenchyma. The
primary site appeared necrotic consistent with recent
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showed that the lesion extended into the body of the right
ventricle and significantly reduced ventricular volume
(Figure 2). The edges of the lesion were fimbriated and
mobile, consistent with a metastatic deposit. Although the
platelet count and clotting improved with Vitamin K and
plasma, the platelet count did not rise above 50. This was
adequate in controlling her haematuria and further treat-
ments were therefore not initiated. As the patient did not
show any overt signs of thrombosis, we did not institute
therapy with anticoagulants. As the patient's functional
status was declining, we were unable to consider chemo-
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was considered but the patient deteriorated and died three
months later. A request to perform an autopsy was refused
by the patient's family.
Discussion
Although a hypercoagulable state exists in virtually all
patients with malignancy, the incidence of overt DIC is
much lower [3]. The aetiology of the activation of coagu-
lability in malignancy is multifactorial and poorly under-
stood. Molecular changes which may influence
hypercoagulability include the expression of tissue factor
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lant by circulating tumour cells [4].
TF assembles with factor VIIa to activate factors IX and X
thereby triggering thrombin formation. TF has been dem-
onstrated to exist in normal vascular endothelial cells sug-
gesting a role in initiating rapid activation of coagulation.
It is rarely expressed in normal epithelial tissue but has
been found to be expressed in malignant tissue such as
breast cancer, whilst not being present in patients with
benign fibrocystic disease [5]. The degree of tissue factor
expression has been shown to correlate with metastatic
potential and histological differentiation such that
increased TF expression results an increased potential to
metastasise and a more undifferentiated histological
appearance [6,7]. Cancer procoagulant has been found in
malignant and foetal tissue, but not in normally differen-
tiated tissue[8,9]. Its only known property is the calcium
and vitamin K dependent conversion of factor X into Xa,
independent of the TF / factor VIIa complex. Hepsin, a
protease found on hepatocyte surface membranes but also
in several tumour cell lines, has been shown to initiate
coagulation by activating factor VIIa independent of TF
[10].
The heart is an under-recognised site of metastatic disease
in patients with cancer. In one series, the incidence at
autopsy was 1.25%. The commonest types of malignancy
to spread to the heart in this series were lung and oesopha-
geal cancers as well as lymphomas [11]. This reflects the
direct proximity of these tumours to the heart, with direct
invasion being the likely pathogenesis. Lung, breast, soft
tissue carcinomas, renal cell carcinomas, lymphomas and
melanoma are most frequently associated with cardiac
involvement. This usually results in pericardial or epicar-
dial disease, with endocardial metastases being less com-
mon. There are reports of cardiac metastases from
metastatic TCC in the literature, however we could find
only one other report of a patient with a cardiac metas-
tases presenting with DIC [12] and this was associated
with cervical carcinoma.
The mechanism of DIC in the described case is speculative
but may relate to the activation of coagulation pathways
directly by the interaction of tumour antigens with plasma
[13]. The postulated mechanism of DIC in this case is the
direct exposure of tumour cells within the right ventricle
to circulating plasma, thus triggering direct activation of
the coagulation cascade through mechanisms mentioned
above. Although we are unable to prove causality, given
that TCC is rarely associated with DIC and that this phe-
nomenon only developed when the tumour metastasised
to the patient's heart; this explanation appears more plau-
sible than the assumption that the patients malignancy
alone resulted in DIC.
Conclusion
This case demonstrates that cardiac metastases should be
considered in all cancer patients with otherwise unex-
plained DIC and that this may influence treatment
choices.
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